Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Adachi, J.D.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(8)
+
-
Availability
Metadata Only
(8)
+
-
Creation Date
2012
(2)
+
-
2013
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(8)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(8)
+
-
Topic
Osteoporosis
(3)
+
-
Author
Adachi, J.D.
(8)
+
-
Papapoulos, S.
(7)
+
-
Wagman, R.B.
(6)
+
-
Bone, H.G.
(5)
+
-
Wang, A.
(4)
+
-
Benhamou, C.L.
(3)
+
-
Bolognese, M.A.
(3)
+
-
Boonen, S.
(3)
+
-
Daizadeh, N.
(3)
+
-
Dakin, P.
(3)
+
-
Farrerons, J.
(3)
+
-
Hadji, P.
(3)
+
-
Halse, J.
(3)
+
-
Lin, C.J.F.
(3)
+
-
Lippuner, K.
(3)
+
-
Minisola, S.
(3)
+
-
Recknor, C.
(3)
+
-
Torring, O.
(3)
+
-
Daizadeh, N.S.
(2)
+
-
Ferrari, S.
(2)
+
-
Franchimont, N.
(2)
+
-
Gallagher, J.C.
(2)
+
-
Man, Z.
(2)
+
-
McClung, M.R.
(2)
+
-
Show more
Language
en
(8)
+
-
Search results
(1 - 8 of 8)
show grid
show list
save search
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study
Evolution of subject characteristics in FREEDOM and its extension for up to 8 years
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
Low incidence of fracture maintained with long-term denosumab treatment in women aged >= 75 years with postmenopausal osteoporosis
DENOSUMAB (DMAB) TREATMENT FOR 6 YEARS MAINTAINS LOW FRACTURE INCIDENCE IN WOMEN >= 75 YEARS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO)
Management of Glucocorticoid-Induced Osteoporosis
Low Fracture Incidence Is Maintained in Postmenopausal Women >= 75 Years with Osteoporosis with Long-Term Denosumab Treatment